Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Congenital leptin deficiency Indication Strategy Report 2026: LEPR, Trials and Deals
24 July 2026
2026 Congenital leptin deficiency strategy: epidemiology, LEPR biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Bardet-Biedl syndrome Indication Strategy Report 2026: MC4R, Trials and Deals
24 July 2026
2026 Bardet-Biedl syndrome strategy: epidemiology, MC4R biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Alström syndrome Indication Strategy Report 2026: ALMS1, Trials and Deals
24 July 2026
2026 Alström syndrome strategy: epidemiology, ALMS1 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Familial partial lipodystrophy Indication Strategy Report 2026: LMNA, Trials and Deals
24 July 2026
2026 Familial partial lipodystrophy strategy: epidemiology, LMNA biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Succinic semialdehyde dehydrogenase deficiency Indication Strategy Report 2026: ALDH5A1, Trials and Deals
24 July 2026
2026 Succinic semialdehyde dehydrogenase deficiency strategy: epidemiology, ALDH5A1 biology, clinical competition, recent deals, unmet need and market…
Latest Hotspot
8 min read
Pyruvate carboxylase deficiency Indication Strategy Report 2026: PC, Trials and Deals
24 July 2026
2026 Pyruvate carboxylase deficiency strategy: epidemiology, PC biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Pyruvate dehydrogenase deficiency Indication Strategy Report 2026: PDHA1, Trials and Deals
24 July 2026
2026 Pyruvate dehydrogenase deficiency strategy: epidemiology, PDHA1 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Mitochondrial encephalomyopathy Indication Strategy Report 2026: POLG, Trials and Deals
24 July 2026
2026 Mitochondrial encephalomyopathy strategy: epidemiology, POLG biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Glutaric acidemia type II Indication Strategy Report 2026: ETFDH, Trials and Deals
24 July 2026
2026 Glutaric acidemia type II strategy: epidemiology, ETFDH biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Nonketotic hyperglycinemia Indication Strategy Report 2026: GLDC, Trials and Deals
24 July 2026
2026 Nonketotic hyperglycinemia strategy: epidemiology, GLDC biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome Indication Strategy Report 2026: SLC25A15, Trials and Deals
24 July 2026
2026 Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome strategy: epidemiology, SLC25A15 biology, clinical competition, recent deals, unmet need and…
Latest Hotspot
8 min read
Argininosuccinic aciduria Indication Strategy Report 2026: ASL, Trials and Deals
24 July 2026
2026 Argininosuccinic aciduria strategy: epidemiology, ASL biology, clinical competition, recent deals, unmet need and market attractiveness.